FREQUENTLY ASKED QUESTIONS
What is the purpose of the study?
The purpose of the study is to determine whether switching to an IL23 inhibitor (guselkumab) is more effective than switching to a second TNF inhibitor (golimumab) for people with psoriatic arthritis (PsA) who either didn't respond or lost response to a TNFi.
See the ABOUT THE STUDY tab for more details.
What is involved in participating?
If you would like to participate, we will schedule you for a screening visit at one of our study centers to confirm that you are eligible. If you are eligible following screening, you will be randomized to one of the three treatment arms, and study drug will be shipped to your home. You would have remote study visits at home every 4 weeks (injection of the study drug and completion of online questionnaires) and 2 in-person visits (at 6 and 12 months). Total participation would last about one year.
What type of clinical trial is this?
This is a randomized, open-label, pragmatic, Phase IIIB clinical trial. The study drugs in this trial are guselkumab (Tremfya) and golimumab (Simponi), which are both approved by the U.S. Food and Drug Administration (FDA) for treatment of active psoriatic arthritis in adults.
How do I participate?
If you are an adult with a diagnosis of psoriatic arthritis and you live in an area where you can visit one of the participating study centers, you can fill out the contact form at the bottom of the page. Someone from our study team will reach out to schedule your screening visit.
Will I need to pay anything?
You will not need to pay anything to participate in the study. The costs of study drug and study-specific testing are covered. If you have health insurance, clinical visits and bloodwork may be billed, so your usual co-pays may apply.
Where is the study being conducted?
The STUDY SITES tab includes information about participating centers.
How will I know if I'm eligible?
If you are aged 18-80, have been diagnosed with psoriatic arthritis, are currently on a TNFi (or have tried one in the past) and you feel like it's not helping your PsA symptoms, and are willing to travel to a participating study center near you, you may be eligible. At your screening visit, the study team will review your full medical history, disease activity, and other criteria to confirm your eligibility.
Will I receive compensation?
You will receive compensation for your time at both the in-person and remote study visits.
Can I leave the study at any time?
Yes! Participation in the study is completely voluntary, and you can choose to discontinue participation at any time.
How long will the study last?
Your study participation will last for about one year. During that time, you will have 3 in-person study visits and remote visits (study drug injection and online questionnaires) every 4 weeks.
Can I participate if I don't want to take any medication?
No, this study is for people who are ready to switch medications for psoriatic arthritis.
Will transportation be provided to the study sites?
At this time, transportation will not be provided. Reimbursements for travel expenses or parking may be covered.
If you have any further questions, please reach out to us on the contact form or via email!
INTERESTED?
Please complete this contact form!
​
Someone on our study team will follow up with you as soon as possible!